Rhinase D Gel Moisturizing Nasal Decongestant

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, and upper respiratory allergies. It also provides temporary relief from sinus congestion and pressure. Additionally, this medication acts to shrink swollen nasal membranes, facilitating easier breathing.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

For adults and children aged 6 to under 12 years, the recommended administration involves placing a small amount of the product in each nostril and inhaling deeply into the nasal passages. This should not be performed more frequently than every 10 to 12 hours, and the total number of doses should not exceed 2 in any 24-hour period.

For children under 6 years of age, it is advised to consult a physician prior to use.

To properly use the product, the user should press down on the grooved white cap firmly and turn it counterclockwise. It is important to secure the cap after each use to maintain product integrity.

Contraindications

There are no specific contraindications listed for this product. However, it is essential to adhere to the following usage guidelines to ensure safety and efficacy:

• Do not exceed the recommended dosage.

• Do not use for more than three consecutive days. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion.

• The use of this container by multiple individuals may increase the risk of infection transmission.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this medication.

Patients should be advised to consult a physician if they have a history of heart disease, high blood pressure, difficulty urinating due to thyroid disease, diabetes, or an enlarged prostate gland. These conditions may influence the safety and efficacy of the treatment.

It is crucial to adhere strictly to the recommended dosage. Patients should not exceed the directed use and should limit the duration of use to no more than three days. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion. Temporary side effects, including burning, stinging, sneezing, or increased nasal discharge, may occur during treatment. Additionally, the use of this medication by multiple individuals can pose a risk of spreading infection.

In the event of accidental ingestion, immediate medical assistance should be sought, or a poison control center should be contacted without delay.

Patients are advised to discontinue use and consult a healthcare provider if symptoms persist. Monitoring for these symptoms is essential to ensure patient safety and effective management of their condition.

Side Effects

Patients should be aware of certain warnings associated with the use of this medication. It is advised to consult a healthcare professional if there is a history of heart disease, high blood pressure, difficulty urinating due to thyroid disease, diabetes, or an enlarged prostate gland.

In the event that symptoms persist, patients are instructed to discontinue use and seek medical advice. This precaution is essential to ensure the safety and well-being of individuals who may have underlying health conditions that could be exacerbated by the medication.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Rhinase D Gel Moisturizing Nasal Decongestant (oxymetazoline hcl 0.5%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may use the product under adult supervision. A small amount should be placed in each nostril and inhaled well back into the nasal passages, not more frequently than every 10-12 hours, with a maximum of 2 doses in any 24-hour period.

For children under 6 years of age, it is advised to consult a doctor before use.

Geriatric Use

Elderly patients may not have specific recommendations regarding age considerations, dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the potential for altered pharmacokinetics and pharmacodynamics in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered, as the effects on fetal outcomes and breastfeeding infants are not fully established. It is essential for women of childbearing potential to discuss their individual circumstances with a healthcare provider to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential. If symptoms of overdosage are observed, appropriate interventions should be implemented based on the patient's condition.

Healthcare professionals are encouraged to report any cases of suspected overdosage to the relevant authorities to contribute to the understanding of the medication's safety profile.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

Postmarketing experience has revealed reports of various adverse reactions associated with the use of the product. These include nasal irritation, a burning sensation in the nasal passages, sneezing, increased nasal discharge, and rebound congestion with prolonged use.

Additionally, there have been rare reports of systemic effects, which encompass hypertension, palpitations, headaches, and dizziness. Cases of allergic reactions have also been documented, including rash, itching, and swelling. Furthermore, some patients have experienced a worsening of pre-existing conditions, such as asthma and chronic obstructive pulmonary disease (COPD).

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children and to seek medical help or contact a poison control center immediately if the medication is swallowed. Patients should be instructed not to exceed the recommended dosage and to refrain from using the medication for more than three days. It is important to emphasize that the medication should only be used as directed, as frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Patients may experience temporary discomfort, which can include burning, stinging, sneezing, or an increase in nasal discharge. Healthcare providers should inform patients that the use of this container by more than one person may increase the risk of spreading infection. Finally, patients should be advised to stop using the medication and consult a doctor if their symptoms persist.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Rhinase D Gel Moisturizing Nasal Decongestant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)